Core Viewpoint - The new drug for treating Type 2 diabetes demonstrates superior efficacy compared to Novo Nordisk's oral semaglutide in improving blood sugar levels and facilitating weight loss [1] Group 1 - The drug showed greater improvements in blood sugar levels, specifically A1C, compared to the competitor [1] - The weight loss results from the new drug were also more significant than those achieved with Novo Nordisk's treatment [1]